Stockscreener 앱 받기
13.87
1.09%
0.15
시간 외 거래:
13.70
-0.17
-1.23%
전일 마감가:
$13.72
열려 있는:
$13.63
하루 거래량:
828.50K
Relative Volume:
0.49
시가총액:
$1.44B
수익:
-
순이익/손실:
$-135.21M
주가수익비율:
-9.6918
EPS:
-1.4311
순현금흐름:
$-114.35M
1주 성능:
+2.74%
1개월 성능:
+31.47%
6개월 성능:
+38.84%
1년 성능:
+39.68%
1일 변동 폭
$13.40
$13.90
1주일 범위
$13.12
$14.12
52주 변동 폭
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
13.87 | 1.43B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-12 | 재개 | Stifel | Buy |
| 2026-05-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-11-20 | 개시 | Evercore ISI | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
HC Wainwright Issues Pessimistic Outlook for ORIC Earnings - marketbeat.com
Understanding Momentum Shifts in (ORIC) - Stock Traders Daily
AVLN Stock Price and Chart — NASDAQ:AVLN - TradingView
Price to book forward of Oric Pharmaceuticals, Inc. – HAM:4TZ - TradingView
What is HC Wainwright's Forecast for ORIC Q1 Earnings? - marketbeat.com
ORIC Pharmaceuticals, Inc. (ORIC) options chain - Yahoo Finance Australia
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25 - webull.com
ORIC Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus
H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress - Investing.com
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally - Sahm
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC - marketbeat.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses? - Yahoo Finance
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Promising Biotech with 60% Upside Potential - DirectorsTalk Interviews
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC? - Sahm
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25 - moomoo.com
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 12.3% HigherHere's What Happened - MarketBeat
Stock Traders Purchase High Volume of Put Options on Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals (ORIC) Projected to Release Earnings on Tuesday - MarketBeat
ORIC SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
ORIC Pharmaceuticals (ORIC) Launches Pivotal Phase 3 Trial Amid Mixed Market Signals - GuruFocus
Oric Pharmaceuticals, Inc. 6M 2026: Net loss $(77.3M), Diluted EPS $(0.72) — 10-Q Summary - TradingView
ORIC: Net loss rose to $77.3M as R&D spending increased; cash runway extends into H2 2028 - TradingView
ORIC: Advanced late-stage oncology pipeline with strong cash position and key trials underway - TradingView
Oric Pharmaceuticals reports Q2 2026 net loss $41.5M, cash $387.6M; Phase 3 trial initiated - TradingView
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates - The Manila Times
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2%Should You Sell? - MarketBeat
Defilade Capital Management L.P. Purchases Shares of 842,928 Oric Pharmaceuticals, Inc. $ORIC - marketbeat.com
Avoiding Lag: Real-Time Signals in (ORIC) Movement - Stock Traders Daily
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan - The Globe and Mail
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 77.77% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
Vivo Capital LLC Cuts Stake in Oric Pharmaceuticals, Inc. $ORIC - marketbeat.com
ORIC Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ORIC Pharmaceuticals Director Richard Heyman Reports Major Stock Transactions on July 24, 2026 - Kalkine Media
Oric Pharmaceuticals Inc (ORIC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oric Pharmaceuticals Inc (ORIC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oric Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ORIC - TradingView
Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ORIC|Oric Pharmaceuticals Inc|Price:13.500|Chg%:+0.570 - TradingKey
Orbimed Advisors LLC Reduces Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210 - TradingKey
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence - TradingKey
Does ORIC (ORIC) Retaining Rinzimetostat Rights Hint At A High-Conviction, High-Risk Development Strategy? - Sahm
Oric Pharmaceuticals Inc (ORIC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen - marketbeat.com
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):